News

Next-gen blockbuster hits PBS

Posted 2 February 2026 AM 

Vertex’s next-generation cystic fibrosis treatment Alyftrek has officially started its run to blockbuster status in Australia after being listed on the PBS over the weekend alongside the first rival of Bayer’s Eylea.

The once-daily tablet, also known as ‘the Vanza triple’ combines three active ingredients – vanzacaftor, tezacaftor and deutivacaftor – that work together to directly target the underlying genetic cause of the condition. It is indicated for the treatment of CF in patients aged 6 years and older who have at least one mutation in the CFTR gene that is responsive to Alyfrek potentiation based on clinical and/or in vitro assay data.

To see the whole article, please login